Skip to main content
. 2019 Sep 4;26(1):1073274819870549. doi: 10.1177/1073274819870549

Table 7.

Hepatocellular carcinoma.

Molecular Feature Target of Therapies Drug(s)
VEGFR-2 VEGFR-2 + cells Regorafenib, Nivolumab. Cabozantinib, Ramucirumab
MAPK pathway MAPK Sorafenib, Lenvatinib

Abbreviations: MAPK, mitogen-activated protein kinase; VEGFR, vascular endothelial growth factor receptor.